The future is now: Gene therapy to take flight in Europe

Nov RedWhiteDNALinkingUp GeneTherapyGlybera

After many years of crushed expectations, gene therapy could be close to a victory: a regulatory approval.

The European Medicines Agency has recommended approval of a gene therapy to treat a rare genetic disease, called lipoprotein lipase deficiency, which prevents people from digesting fat. The drug, called Glybera, created by Dutch-based company uniQure, had previously been rejected by the EMA three times.

This recommendation still requires approval by the European Commission, which is expected within three months. Many anticipate that the drug will be approved, due to the fact that the EC generally follows advice from the EMA.

If Glybera is indeed approved, it will be the first commercial gene therapy to win regulatory approval in the West. The only additional gene therapy drug commercially available is Gendicine, which is used in China to treat cancer.

It is still unclear whether or not uniQure will apply for FDA approval for US marketing.

Additional Resources:

Outbreak
Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
Infographic: What are mRNA COVID-19 vaccines and how do they work?

Infographic: What are mRNA COVID-19 vaccines and how do they work?

As of 1 December 2020, thirteen vaccines have reached the final stage of testing: where they are being given to ...
favicon

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

Optional. Mail on special occasions.
Send this to a friend